CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 29 enrolled
Drug / intervention
PCLX-001 - 20mg +6 moredrug
Likely dose
PCLX-001 - 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04836195
NCT04836195Phase 1Completed
CompareCT.gov

Phase I Trial of PCLX-001 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies

Pacylex Pharmaceuticals·interventional·Posted Apr 8, 2021·Updated Apr 17, 2025

In Brief

A Phase 1 clinical trial evaluating PCLX-001 - 20mg, PCLX-001 - 40mg, and 5 other interventions for B-cell Non Hodgkin Lymphoma and Advanced Solid Tumor. Completed, enrolled 29 participants across 4 sites.

Detailed Summary

This is a phase I dose-escalation study of oral PCLX-001, conducted in a multicenter, non-randomized, open-label, non-controlled design. The study is comprised of two parts: Part A (single-agent dose escalation) and Part B (single-agent expansion cohorts).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Non Hodgkin Lymphoma, Advanced Solid Tumor
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedApr 8, 2021
Enrollment StartSep 14, 2021
Primary CompletionOct 28, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 5.2 years ago

Interventions

PCLX-001 - 20mgdrug

20mg daily oral pills

PCLX-001 - 40mgdrug

40mg daily oral pills

PCLX-001 - 70mgdrug

70mg daily oral pills

PCLX-001 - 100mgdrug

100mg daily oral pills

PCLX-001 - 140mgdrug

140mg daily oral pills

PCLX-001 - 210mgdrug

210mg daily oral pills

PCLX-001 - 280mgdrug

280mg daily oral pills